Carboplatin/Etoposide vs Topotecan as Second-Line Treatment in Sensitive Relapsed Small-Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology